Seasonal Affective Disorder (SAD)

The short version

●Seasonal affective disorder (SAD) is the colloquial term for major depressive disorder with the "with seasonal pattern" specifier in DSM-5-TR — major depressive episodes occurring with regular temporal pattern (most commonly fall/winter onset, spring/summer remission) for at least two consecutive years.
●Winter-onset SAD predominates (~90% of cases). Symptoms often include atypical features: hypersomnia, hyperphagia (carbohydrate craving), weight gain, fatigue, and social withdrawal. Different phenomenology from typical major depression.
●Summer-onset SAD (~10% of cases) is less common and typically presents with insomnia, agitation, weight loss, and decreased appetite — phenomenology more similar to typical major depression.
●First-line treatments: bright light therapy (10,000 lux, 30 min morning, sustained through symptomatic season) and CBT-SAD (Rohan's manualized cognitive-behavioral therapy for SAD). Effect sizes are comparable; combination outperforms either alone.
●SSRIs (sertraline, fluoxetine, escitalopram) and bupropion XL (which has FDA approval for SAD prevention specifically) are second-line. Many patients use a seasonal schedule: start treatment in fall, continue through symptomatic season, taper in spring.
●Ketamine's evidence in SAD specifically is limited; clinical use for treatment-resistant SAD draws on the broader antidepressant mechanism. Summer-onset SAD with its more typical major-depression phenomenology may respond similarly to other forms of major depression.

Clinical definition

DSM-5-TR criteria for the "with seasonal pattern" specifier on a major depressive episode: (1) regular temporal relationship between onset of major depressive episodes and a particular time of year (e.g., fall or winter); (2) full remissions or change in episode polarity occur at characteristic time of year (e.g., spring); (3) within last 2 years, two major depressive episodes have demonstrated the seasonal pattern and no non-seasonal episodes have occurred during the same period; (4) seasonal major depressive episodes substantially outnumber non-seasonal episodes lifetime. The seasonal pattern can apply to bipolar disorder as well as MDD. Winter-onset is most common and typically features atypical depression phenomenology (hypersomnia, hyperphagia, leaden paralysis, interpersonal rejection sensitivity). Summer-onset is less common and features more typical melancholic phenomenology. Mechanism is multifactorial: circadian phase delay (shorter daylight, later sunrise advances dim-light melatonin onset to later in the morning), serotonergic dysregulation (lower serotonin transporter availability in winter in some studies), and reduced light exposure as a behavioral mediator. ICD-10 does not have a distinct SAD code; it is captured as recurrent depressive disorder.

How it differs from related conditions

vs. "Winter blues" (sub-syndromal)

Many people experience modest seasonal mood changes (lower energy, more sleep, less social engagement) in winter without meeting major depressive episode criteria. Sub-syndromal seasonal mood change can warrant light therapy as a lifestyle intervention but does not meet DSM-5-TR criteria for the seasonal pattern specifier.

vs. Bipolar disorder with seasonal pattern

Bipolar 1 or bipolar 2 with seasonal pattern is well-recognized — typically winter depression with spring/summer hypomania or mania. Treatment differs substantially from unipolar seasonal depression (mood stabilizer foundational; light therapy used with caution because of potential to trigger mood elevation). Distinguishing matters.

vs. Recurrent MDD without seasonal pattern

The "with seasonal pattern" specifier requires consistent temporal relationship over 2+ years AND seasonal episodes substantially outnumbering non-seasonal episodes lifetime. Patients who happen to have had two winter episodes but also have non-seasonal episodes do not meet the specifier criteria.

vs. Persistent depressive disorder (PDD) with seasonal exacerbations

PDD patients may experience seasonal worsening on top of their chronic baseline. This is captured by PDD with the appropriate specifiers and does not constitute SAD per se. Treatment combines PDD management with seasonal interventions (light therapy, schedule adjustment).

First-line treatments

Bright light therapy (10,000 lux, morning)

First-line treatment for winter-onset SAD. 10,000 lux fluorescent light box, 30 minutes within first hour of waking, daily through the symptomatic season. Position 16-24 inches from face, eyes open but not looking directly at light. Onset of effect 1-2 weeks. Tolerability good; mild side effects (headache, eye strain) usually resolve with positional adjustment. Mechanism: phase advance of circadian system + serotonergic modulation.

CBT-SAD (Rohan's manualized protocol)

Cognitive-behavioral therapy specifically adapted for SAD — addresses seasonal-specific cognitions ("winter is misery"), behavioral activation despite reduced energy and daylight, and proactive prevention strategies for subsequent seasons. Effect sizes comparable to light therapy. Durability across subsequent seasons is a notable advantage — Rohan and colleagues' work shows CBT-SAD gains persist into the next winter while light therapy effects do not without continued use.

SSRIs (sertraline, fluoxetine, escitalopram)

Second-line pharmacotherapy. Reasonable when light therapy and CBT-SAD are insufficient or impractical. Some patients use a seasonal schedule: start SSRI in fall before symptom onset, continue through symptomatic season, taper after spring remission. Standard antidepressant titration and duration considerations apply.

Bupropion XL (prevention indication)

FDA-approved specifically for SAD prevention (not treatment). Started in autumn before symptom onset and continued through early spring. Particularly useful for patients with prior winter episodes whose response is predictable enough to warrant prophylaxis. Avoids the lag-to-effect issue of starting acute treatment after symptoms emerge.

Vitamin D supplementation (modest role)

Vitamin D deficiency is more common in winter; correction is reasonable. The evidence for vitamin D as PRIMARY SAD treatment is weak; effect sizes modest. Reasonable as adjunct given low cost and broader health benefits in deficiency. Not a substitute for light therapy or CBT-SAD.

Behavioral activation and outdoor time

Structured outdoor time (even on cloudy winter days, outdoor light exceeds typical indoor light by 10-100x) and behavioral activation programs increase mood-relevant activity. Particularly relevant for patients whose SAD is worsened by self-imposed indoor isolation during winter months.

Dawn simulators

Alarm clocks that gradually brighten over 30-90 minutes before wake time. Smaller body of evidence than full light boxes but useful for patients whose primary symptom is morning lethargy and difficulty waking. Some patients respond to dawn simulation when they cannot tolerate dedicated light-box sessions.

When standard treatments fail

For treatment-resistant SAD: combine light therapy with CBT-SAD if only one was used → add SSRI alongside light therapy → switch SSRI or trial bupropion XL → consider seasonal augmentation with second-generation antipsychotic during peak symptom season → consider rTMS → consider rapid-acting options including ketamine for severe seasonal episodes with suicidality. For summer-onset SAD (a smaller but real subset), light therapy is contraindicated (can worsen symptoms); treatment follows the typical MDD pathway. Patients with multiple consecutive seasons of recurrent SAD often benefit from a chronic prevention strategy (bupropion XL or low-dose SSRI started in fall) rather than acute treatment each year.

Where ketamine fits

Ketamine in seasonal affective disorder specifically has not been the subject of dedicated RCTs. Clinical use draws on the broader antidepressant mechanism, with relevance to treatment-resistant SAD or patients whose seasonal pattern is severe enough to warrant rapid-acting intervention rather than waiting 4-8 weeks for SSRI onset during a time-limited symptomatic season. The intra-season acceleration of response is a practical consideration — by the time conventional treatment reaches full effect, the symptomatic season may already be ending. Ketamine's rapid onset is potentially well-matched to time-limited seasonal patterns. For summer-onset SAD with its more typical major-depression phenomenology, ketamine likely has efficacy similar to other forms of MDD. Patients with prior bipolar history and seasonal pattern require concurrent mood stabilizer (see /conditions/bipolar-2-depression).

Where this fits with Tovani

Tovani treats SAD when first-line treatments (light therapy, CBT-SAD) and standard pharmacotherapy have been adequately tried. The seasonal-pattern history is captured in eligibility screening. For patients with predictable annual recurrence, the conversation may shift toward seasonal prevention strategies (bupropion XL prophylaxis, structured light therapy schedule) alongside ketamine for active symptomatic seasons. The clinic's telehealth model is well-suited to seasonal patients who may need treatment intensification during winter and tapering during summer.

Check eligibility The science behind ketamine

Frequently asked

How do I know if I have SAD versus just disliking winter?

Two diagnostic criteria distinguish: temporal pattern (at least two consecutive years of major depressive episodes with seasonal onset and remission) and severity (episodes meet criteria for major depression, not just sub-syndromal mood changes). A clinical evaluation reviews lifetime episode pattern. The Personal Inventory for Depression and SAD (PIDS) is a useful screening tool that captures both seasonal pattern and severity.

Does light therapy actually work?

Yes, with effect sizes comparable to SSRIs in winter-onset SAD. The protocol matters: 10,000 lux, 30 minutes, within first hour of waking, daily through the symptomatic season. Lower-intensity devices, shorter sessions, or evening use can produce minimal or negative effects. Investment in a properly-specified light box is worthwhile.

Can I just start SSRIs in October to prevent winter SAD?

Bupropion XL has FDA approval specifically for SAD prevention started in autumn. SSRIs can be used in similar seasonal schedules (start before predictable symptom onset, taper after spring remission) but are not specifically FDA-approved for prevention. Patients with documented multi-year recurrence often benefit from this prophylactic approach.

Will ketamine work for my SAD?

The SAD-specific evidence base is small, but ketamine's rapid-acting mechanism is potentially well-matched to time-limited seasonal episodes where the 4-8 week SSRI onset lag is problematic. Ketamine becomes more reasonable when light therapy and CBT-SAD have been adequately tried and SSRIs have failed. For summer-onset SAD with typical major-depression phenomenology, ketamine likely has efficacy similar to other forms of MDD.

What about summer-onset SAD?

Summer-onset SAD (~10% of seasonal cases) typically presents with insomnia, agitation, weight loss, and decreased appetite — phenomenology more like typical major depression than winter-onset SAD. Light therapy is contraindicated and can worsen symptoms. Treatment follows the typical MDD pathway: SSRIs first-line, CBT, and for treatment-resistant cases, options including ketamine.

References

Rohan KJ et al. 2023, Behavior Therapy — Mediational analysis of CBT-SAD trial — change in seasonal beliefs mediates the durability advantage of cognitive-behavioral therapy versus light therapy across subsequent winters in SAD. (PMID 37330257)
Cipriani A et al. 2018, Lancet — Network meta-analysis of antidepressants in adult depression — comparative effect sizes informing SSRI and bupropion selection in seasonal depressive episodes. (PMID 29477251)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression — foundational rapid-acting antidepressant evidence with relevance to time-limited seasonal episodes where SSRI onset lag is clinically problematic. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.